

## **Covalon To Showcase IV Clear To Pediatric Specialists At The Association For Vascular Access Annual Meeting**

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Sep. 16, 2016-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be presenting the latest version of IV Clear™ at the Association for Vascular Access ("AVA") Annual Scientific Meeting. In addition to the main event, Covalon will be one of a limited number of industry participants at the AVA Pediatric Special Interest Group's pre-meeting educational workshop. IV Clear is the only dual antimicrobial clear silicone adhesive securement dressing that protects patients from bacteria and yeast, while also protecting them from unnecessary skin damage commonly found with the use of other vascular access dressings.

AVA's Annual Scientific Meeting is the premier event dedicated to scientific research and clinical best practices within vascular access and will be held from September 16 to September 19, 2016. The annual meeting provides Covalon the opportunity to engage in educational sessions, professional development roundtables, hands-on clinical training, new product demonstrations, and networking with over 1,400 vascular access professionals.

"This year's AVA meeting will provide Covalon with a platform to introduce the advancements made with IV Clear to leading vascular access professionals," said Brian Pedlar, Covalon's Chief Executive Officer. "AVA provides us a convenient forum to personally connect with the clinicians in the United States that use IV Clear every day on pediatric, oncology and sensitive skin patients who require antimicrobial protection along with vascular catheter insertions. Our recent victory with IV Clear being selected as the exclusive antimicrobial vascular access dressing in Saudi Arabia Ministry of Health hospitals and clinics provides a good reference point for Covalon to expand the use of IV Clear on any patient with a vascular catheter or other percutaneous device inserted through their skin."

IV Clear™ is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most commonly associated blood stream infection bacteria<sup>1</sup> and its skin sparing silicone adhesive will not cause adhesive related skin injury or pain during dressing changes<sup>2</sup>.

The Association for Vascular Access is an association of healthcare professionals founded in 1985 to promote the emerging vascular access specialty. Today, it's multidisciplinary membership advances research, professional and public education to shape practice and enhance patient outcomes, and partners with the device manufacturing community to bring about evidence-based innovations in vascular access. AVA is the leader in defining the standards of vascular access through an evidence-based approach, resulting in enhanced healthcare outcomes.

From September 16-19, 2016, please visit us at booth #108 at the Coronado Springs Resort, Lake Buena Vista, Florida.

### **About Covalon**

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at [www.covalon.com](http://www.covalon.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for*

*additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.*

i A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22

ii A Human Repeat Patch Test Study, DiTizio et al. <http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters>

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160916005079/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.

Brian Pedlar, 905-568-8400 x 233

CEO

[bpedlar@covalon.com](mailto:bpedlar@covalon.com)

Toll free: 1-877-711-6055

Web site: [www.covalon.com](http://www.covalon.com)

Twitter: @covalon

---

<https://ir.covalon.com/press-releases?item=180>